The following criteria is provided for health care professionals.

Inclusion Criteria:

• Written informed consent obtained prior to any screening procedures and in accordance with federal, local, and institutional guidelines.
• Age ≥ 18 years.
• Confirmed diagnosis, and evidence of progressive disease or clinical relapse as defined by International Myeloma Working Group (IMWG) criteria and following prior therapy for MM:
  1. Relapsed or refractory MM requiring current treatment.
  2. Previously failed ≥ 3 prior regimens.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.
• Estimated life expectancy ≥ 4 months.
• No other medical, surgical, or psychiatric condition (including active substance abuse) that would interfere with compliance to the protocol, as determined by the Principal Investigator.
• Female subjects of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at Screening, and male subjects must use an effective barrier method of contraception if sexually active with a female of childbearing potential.
• Subjects need a functioning, central venous access in place for the administration of agenT-797.

Exclusion Criteria:

• Pregnant or nursing women.
• Prior history of invasive malignancy.
• Subjects who had an allogeneic stem cell transplantation and are still on immunosuppressive medications or corticosteroids above physiological dose.
• New York Heart Association Class III or IV heart failure, unstable angina, or a history of recent myocardial infarction.
• Adverse events from prior anticancer therapy that have not resolved to NCI CTCAE Grade ≤ 1.
• Receiving any investigational products within 4 weeks or 5 half-lives of cell infusion.